PubHawk
N Engl J Med September 2009 PMID 19717846

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Lars Wallentin, Richard C Becker, Andrzej Budaj, Christopher P Cannon, Håkan Emanuelsson, Claes Held, Jay Horrow, Steen Husted, Stefan James, Hugo Katus, Kenneth W Mahaffey, Benjamin M Scirica, Allan Skene, Philippe Gabriel Steg, Robert F Storey

Download social card

Mentions

140
Peak: 7 in Mar 2022
across 5 sources since Jan 2019

Extended reach

180,447
potential audience

Total likes

98

Video views

2,537

Mentions per month

Jan 2019 – Jul 2025

Where it's discussed

  • News75 articles
  • X / Twitter38 posts
  • Facebook12 posts
  • Blogs11 articles
  • YouTube4 videos

AI synopsis

What people are saying

The discussions demonstrate a strong consensus on ticagrelor's advantages based on the PLATO trial, with references to its faster action and lower mortality, while others critique aspects like cost or contextual relevance. Words such as 'superiority,' 'beneficial,' and 'controversy' reveal a tone of analytical engagement, emphasizing the clinical importance of the publication.

AgreementModerate agreement

Most discussions acknowledge the evidence from the PLATO trial, supporting ticagrelor's superiority over clopidogrel.

InterestHigh interest

Posts show high interest, referencing detailed studies, clinical implications, and discussing trial results.

EngagementModerate engagement

Participants delve into specifics like side effects, pricing, and real-world applications, indicating active engagement.

ImpactModerate impact

Many posts highlight the potential influence of the study on clinical practice and guidelines, suggesting moderate impact.

Abstract in brief

  • Ticagrelor is a faster-acting, more effective blood thinner than clopidogrel for preventing heart attacks, strokes, and death in patients with acute coronary syndromes.
  • Over 12 months, patients taking ticagrelor had fewer cardiovascular events and a lower death rate compared to those on clopidogrel, with similar rates of major bleeding.
  • While ticagrelor increased some bleeding risks, including more fatal intracranial bleeding, it overall showed better protection against serious heart-related outcomes.
Read the full abstract

Top posts

Most liked on X and Bluesky
ACCP Cardiology PRN
@accpcardprn · X

#TBT Today's Spotlight: PLATO

Mar 17, 2022 · 25 likes · 8 shares · 9,296 followers View post →
Ankur Kalra
@AnkurKalraMD · X

@aayshacader @mirvatalasnag @Hragy @mmamas1973 @rahatheart1 @adityadoc1 @bcostelloMD @jmahmed @stefan_harb @ShariqShamimMD @DrAsifQasim @biljana_parapid Yes; encountered in two patients. There is complete resolution following cessation of ticagrelor. It was reported in the PLATO trial (https://t.co/MlTx28LEhk), but also with clopidogrel. I transitioned the two patients to prasugrel. https://t.co/LuwicEtWzM

Sep 22, 2019 · 12 likes · 4 shares · 15,494 followers View post →
Cardiotipss
@cardiotipss · X

@GPinarCs N Engl J Med 2009; 361:1045-1057 DOI: 10.1056/NEJMoa0904327 Si bien se ha demostrado la superioridad de ticagrelor frente a clopidogrel una gran ventaja de clopidogrel es su precio. Saludos! https://t.co/ZnRjKduL9q

Apr 18, 2022 · 6 likes · 1 share · 15,115 followers View post →
Jay Giri
@jaygirimd · X

Why is this important? Well, current guidelines recommend use of pras/ticag over clopi for P2Y12 inhibition in PCI patients with ACS. This is based mostly on data from PLATO: https://t.co/lLUb5mMEYl & TIMI 38: https://t.co/sf5D2Hbkut

Jan 5, 2019 · 3 likes · 4,069 followers View post →
Akhmetzhan Galimzhanov
@AkhmetzhanG · X

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes | NEJM https://t.co/XP13urBv7V

Mar 26, 2019 · 2 likes · 1 share · 806 followers View post →
Tom Curley, MD
@Curley_MD · X

PLATO Trial, double blind RCT of 18,624 pts who have ACS with or w/o STEMI: tx with ticagrelor compared with clopidogrel reduced the rate of death from vascular causes, myocardial infarction, or stroke w/o increase in the rate of overall major bleeding https://t.co/dVihpPZMJy

Dec 8, 2020 · 2 likes · 475 followers View post →

All mentions

د. نور شرف الراجحي
@DrNooralrajhi · X

RT @DAbdullahSharaf: https://t.co/89TWTD19sB

Jun 14, 2024 · 1 share · 28 followers View post →
Dr. Abdullah Alrajhi د.عبدالله الراجحي
@DAbdullahSharaf · X

https://t.co/89TWTD19sB

Jun 14, 2024 · 1 like · 1 share · 309 followers View post →
Per Svensson persvensson@med-mastodon.com
@PerPersvensson · X

@elmir1omerovic @f2harrell Like this https://t.co/Oj7ZZNSJyn and this https://t.co/HBQfV2Z6BW

Jan 10, 2023 · 2 likes · 208 followers View post →
cardio-met
@cardiomet_CE · X

32) ... into the active form, which can take 2 hours or longer. So it doesn’t start working as fast as ticagrelor. In PLATO (

Sep 14, 2022 · 4,155 followers View post →
s z
@JuaDalas · X

Ticagrelor versus clopidogrel in patients with Acute Coronary Syndromes The Study of Platelet Inhibition and Patient Outcomes (PLATO) investigators Raúl. - ppt descargar https://t.co/jObTsiZX9Q

Aug 18, 2022 View post →
Landmark Trials
@LandmarkTrials · X

Read the original study here: https://t.co/w5rxkiRIki

Jun 7, 2022 · 1 like · 848 followers View post →
Berenice Lopez
@dralopezC · X

RT @cardiotipss: @GPinarCs N Engl J Med 2009; 361:1045-1057 DOI: 10.1056/NEJMoa0904327 Si bien se ha demostrado la superioridad de ticagr…

Apr 18, 2022 · 1 share · 8 followers View post →
Cardiotipss
@cardiotipss · X

@GPinarCs N Engl J Med 2009; 361:1045-1057 DOI: 10.1056/NEJMoa0904327 Si bien se ha demostrado la superioridad de ticagrelor frente a clopidogrel una gran ventaja de clopidogrel es su precio. Saludos! https://t.co/ZnRjKduL9q

Apr 18, 2022 · 6 likes · 1 share · 15,115 followers View post →
Lauren Lacoursiere
@llacours23 · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 18, 2022 · 8 shares · 28 followers View post →
A s m a Malwi
@PhsmSam · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 18, 2022 · 8 shares · 1,000 followers View post →
Erica Sheridan
@sheridan_erica · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 17, 2022 · 8 shares · 392 followers View post →
Drake Meaney
@drakemeaneyrx · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 17, 2022 · 8 shares · 17 followers View post →
Akiva Rosenzveig
@AkivaRosenzveig · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 17, 2022 · 8 shares · 1,584 followers View post →
Jack Pluenneke
@JackPluenneke · X

RT @accpcardprn: #TBT Today's Spotlight: PLATO

Mar 17, 2022 · 8 shares · 785 followers View post →
ACCP Cardiology PRN
@accpcardprn · X

#TBT Today's Spotlight: PLATO

Mar 17, 2022 · 25 likes · 8 shares · 9,296 followers View post →
Dr. ViveK Nuktey
@NukteVivek · X

PLATO ! Ticagrelor Vs Clopidogrel https://t.co/EACWWPCNUG

May 22, 2021 · 600 followers View post →
Prabhakar Dorairaj
@prabhud19 · X

Heard your discussions in India why do you bring PLATO here ? This is a different era. https://t.co/3RX89zad8L. That was 2009. May not apply to US - but in high clop resistant Korea it works - we should give credit

May 22, 2021 · 1,627 followers View post →
Tom Curley, MD
@Curley_MD · X

PLATO Trial, double blind RCT of 18,624 pts who have ACS with or w/o STEMI: tx with ticagrelor compared with clopidogrel reduced the rate of death from vascular causes, myocardial infarction, or stroke w/o increase in the rate of overall major bleeding https://t.co/dVihpPZMJy

Dec 8, 2020 · 2 likes · 475 followers View post →
Abdullah Malik
@AHMalik_MD · X

Treatment with ticagrelor significantly reduces mortality in patients with ACS when compared to clopidogrel. https://t.co/sRZjtjB8MN https://t.co/hXeJnbAL3D

Sep 26, 2020 · 1 like · 393 followers View post →
Dmariag
@Dmariag1 · X

https://t.co/9SuBP25SZB @ fuadfehmi @ MF_JAN_CICUteam https://t.co/MekFNl5JsV

Sep 26, 2020 View post →
Dmariag
@Dmariag1 · X

https://t.co/9SuBP25SZB https://t.co/tWDaaCK5D5

Sep 26, 2020 View post →
Juan Senior
@jsenior64 · X

Luego aparece el estudio PLATO que demuestra mejor efecto de Ticagrelor sobre clopidogrel. Un estudio con resultados sólidos, que deja menor incertidumbre que el TRITON TIMI 38, sin embargo más criticado y con mayor controversia. https://t.co/cY7iO4tdgF

Sep 10, 2020 · 11,070 followers View post →
Mr.Pharmarichie
@richie_thepharm · X

Clopidogrel ▶️ Ticagrelor Ticagrelor- valuable option to reduce the risk of bleeding, MI and stroke S/E: Bleeding, Dyspnoea 1. N Engl J Med 2009; 361:1045-1057 DOI: 10.1056/NEJMoa0904327 2. https://t.co/SWll3Taf9z 3. DOI: 10.1186/s12872-018-0948-4

Apr 16, 2020 · 15 followers View post →
Kamil Faridi MD MSc
@kfaridiMD · X

DAPT with ASA/P2Y12i are standard of care for STEMI. Clopidogrel approved by FDA in 2006. Prasugrel and Ticagrelor later approved based on TRITON and PLATO trials showing increased efficacy compared to clopidogrel: https://t.co/daIE79fbjF https://t.co/wR3HU8xjAz

Mar 12, 2020 · 1 like · 649 followers View post →
Jeremy Faust MD MS (ER physician)
@jeremyfaust · X

For more, see https://t.co/W4Y17oiNUa https://t.co/94Oc30tqNJ https://t.co/fp4XTpHqlL And my piece in Slate https://t.co/PsYTd3rFA0

Feb 21, 2020 · 93,310 followers View post →
名前
@akkiii0830 · X

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Oct 4, 2019 · 246 followers View post →
Aaysha Cader
@aayshacader · X

RT @AnkurKalraMD: @aayshacader @mirvatalasnag @Hragy @mmamas1973 @rahatheart1 @adityadoc1 @bcostelloMD @jmahmed @stefan_harb @ShariqShamimM…

Sep 22, 2019 · 4 shares · 9,067 followers View post →
Ankur Kalra
@AnkurKalraMD · X

@aayshacader @mirvatalasnag @Hragy @mmamas1973 @rahatheart1 @adityadoc1 @bcostelloMD @jmahmed @stefan_harb @ShariqShamimMD @DrAsifQasim @biljana_parapid Yes; encountered in two patients. There is complete resolution following cessation of ticagrelor. It was reported in the PLATO trial (https://t.co/MlTx28LEhk), but also with clopidogrel. I transitioned the two patients to prasugrel. https://t.co/LuwicEtWzM

Sep 22, 2019 · 12 likes · 4 shares · 15,494 followers View post →
Felix Valencia
@FelixValencia10 · X

@Costa_F_8 @PCRonline @nickaram @Ortega_Paz @SABOURETCardio @sbrugaletta @GiuseppeDiGioi9 @NEJM This is a sentence from the PLATO abstract "No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43)". https://t.co/flzicNZmjM

Sep 22, 2019 · 1,705 followers View post →
Troels Yndigegn MD PhD
@YndigegnY · X

ASPIRIN in ACS - RISC https://t.co/tUMD8XJq52 Early INVASIVE treatment in NSTEMI: FRISC-II https://t.co/kW95Su2WT8 Ticagrelor in ACS: PLATO https://t.co/dVpdAyxqEc Dabigatran in AF: RE-LY https://t.co/xhhZ9OfIAZ Apixaban in AF: ARISTOTLE https://t.co/uF3uZhysVi

Sep 11, 2019 · 404 followers View post →
名前
@akkiii0830 · X

日本含めたアジアでの試験 https://t.co/LZJMDmTK2x 国際共同試験 https://t.co/pkALeNlgxw 長期投与試験 https://t.co/y5WFjOH46O freeで読めるのは有難かった

Jul 22, 2019 · 246 followers View post →
Aidan Fischer
@FischerPharm · X

Yes we can - but there are a few considerations. First, there's a reason we use ticagrelor for ACS in the first place - see PLATO from 2008. Ticagrelor is associated with less "MACE" than clopidogrel (NNT 53, see below), but NNH for major bleeding of 142 https://t.co/aQxmDs45Fj https://t.co/NIs8P86o6f

Jun 14, 2019 · 604 followers View post →
Benjamin Stewart
@drbstewart · X

⭐️

Jun 3, 2019 · 1 like · 2,118 followers View post →
Justin Reed Culshaw, Pharm.D. BCCCP
@CulshawReed · X

Quick recap: Ticagrelor is an oral anti-platelet that directly and reversibly inhibits P2Y12 ADP receptors and

May 30, 2019 · 356 followers View post →
Christopher Mayer, MD, MS
@ScienceWChris · X

Is Ticagrelor an antibiotic? Check my video to find out! https://t.co/jlh8EhJMKn #Ticagrelor @AstraZeneca @JAMACardio

May 30, 2019 · 1 like · 115 followers View post →
Carol Artigas Gomez
@cartigasg · X

RT @AkhmetzhanG: Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes | NEJM https://t.co/XP13urBv7V

May 23, 2019 · 1 share · 629 followers View post →
Akhmetzhan Galimzhanov
@AkhmetzhanG · X

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes | NEJM https://t.co/XP13urBv7V

Mar 26, 2019 · 2 likes · 1 share · 806 followers View post →
Jay Giri
@jaygirimd · X

Why is this important? Well, current guidelines recommend use of pras/ticag over clopi for P2Y12 inhibition in PCI patients with ACS. This is based mostly on data from PLATO: https://t.co/lLUb5mMEYl & TIMI 38: https://t.co/sf5D2Hbkut

Jan 5, 2019 · 3 likes · 4,069 followers View post →